Medios AG announced the closure of its Aschaffenburg facility, a wholly owned subsidiary, as part of a strategic optimization of its manufacturing network in Germany. The company is consolidating patient-specific production at its remaining locations, with production already relocated and supplies to pharmacies and hospitals guaranteed. The Aschaffenburg site accounted for approximately 10% of the Medios Group's German production volume and had been operating at below-average profitability with declining capacity utilization. Structural renovation work required at the site accelerated the decision to close it.
The closure affects 32 employees, for whom Medios is seeking fair compensation. The move is part of the company's Operational Excellence Program, aimed at sustainably strengthening profitability. The business of patient-specific formulations faces sustained margin pressure, particularly due to price regulatory adjustments, prompting the company to implement efficiency measures. Medios operates a network of six GMP manufacturing facilities for patient-specific therapies in Germany, and the consolidation will focus on high-performing sites like Mannheim and Stuttgart to ensure reliable supply.
Thomas Meier, CEO of Medios AG, stated: "With a view to ensuring a reliable supply for our customers and maintaining capacity utilization at all sites, we are now optimizing our successful regional presence strategy and consistently developing it further. With Mannheim and Stuttgart, we have two high-performing Medios sites in southern Germany, ensuring that a reliable supply is maintained."
Medios AG is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium, and Spain. The company focuses on individualized medicine and innovative solutions for the pharmaceutical supply chain. Listed on the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index, Medios shares (ISIN: DE000A1MMCC8) are traded on the regulated market. The company will report its half-year financial results on August 12, 2026, and host a Capital Markets Day in Breda on September 28-29, 2026.
This announcement underscores the challenges faced by pharmaceutical manufacturers in Germany due to regulatory price adjustments and the need for operational efficiency to maintain profitability. The closure of the Aschaffenburg site reflects broader industry trends where companies are consolidating operations to adapt to margin pressures and ensure long-term sustainability. Medios' decision to optimize its network while maintaining supply reliability highlights the balance between cost-cutting and service continuity in the specialty pharma sector.
For more information, visit the Medios AG website at https://www.medios.group or view the original release at https://www.newmediawire.com.
